balaglitazone (DRF-2593) / Dr. Reddy’s - LARVOL DELTA

Molecular Cloning, Characterization, and Expression Regulation of Acyl-CoA Synthetase 6 Gene and Promoter in Common Carp Cyprinus carpio. (PubMed, Int J Mol Sci) - "Furthermore, the intraperitoneal injection of PPARγ agonists (balaglitazone) increased the expression of acsl6 mRNA, coupling with an increased proportion of DHA in the muscle, while opposite results were obtained in the injection of the SREBP1c antagonist (betulin). However, the expression of acsl6 and DHA content in muscle were largely unchanged by PPARα agonist (fenofibrate) treatment. These results indicated that acsl6 may play an important role for the muscular DHA uptake and deposition in common carp, and PPARγ and SREBP-1c are the potential TFs involved in the transcriptional regulation of acsl6 gene. To our knowledge, this is the first report of the characterization of acsl6 gene and its promoter in teleosts."

Journal

Balaglitazone: A second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist (Mini Rev Med Chem) - P3, N=409; Balaglitazone treated groups shown significantly reduce of HbA1c (%), FSG (mmol/L), postprandial glucose as comparison to pioglitazone; Drug provides robust glycemic control as an add-on to insulin therapy; Balaglitazone 10mg and 20mg show the similar magnitudes of the effects which comparable to the effects seen in the pioglitazone 45mg group

Review of P3 trials • Diabetes

The promoters of Dr Reddy's Laboratories Ltd have no intention to sell their stake, according to its Managing Director and Chief Operating Officer, Mr K. Satish Reddy (The Hindu Business Line) - Balaglitazone is in late stage of P3 trial;

Pipeline update • Diabetes

The promoters of Dr Reddy's Laboratories Ltd have no intention to sell their stake, according to its Managing Director and Chief Operating Officer, Mr K. Satish Reddy (The Hindu Business Line) -

Balaglitazone is in late stage of P3 trial;

Pipeline update